5AM Ventures Beats Goal for 3rd Fund

Xconomy Boston — 

5AM Ventures, a life sciences-focused early stage venture capital firm, has surpassed its $150 million target for its third fund, reports PE Hub. An SEC filing that indicates 5AM, which has offices in Waltham, MA, and Menlo Park, CA, has raised $159.2 million from 34 investors. Companies in the firm’s portfolio include Pulmatrix, a Lexington, MA-based startup developing an aerosol treatment for flu other pathogens, and Cambridge, MA-based Semprus BioSciences, which is making polymers that bond to the surface of medical devices to prevent clots and infections and to promote healing.